Episode Details
Back to Episodes
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline
Published 10 months ago
Description
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.